Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
OlympiA III期临床试验中，奥拉帕尼辅助治疗对携带BRCA1/2种系致病性变异的高危早期乳腺癌患者的总生存期
期刊:Annals of Oncology
影响因子:65.4
doi:10.1016/j.annonc.2022.09.159
Geyer, C E Jr; Garber, J E; Gelber, R D; Yothers, G; Taboada, M; Ross, L; Rastogi, P; Cui, K; Arahmani, A; Aktan, G; Armstrong, A C; Arnedos, M; Balmaña, J; Bergh, J; Bliss, J; Delaloge, S; Domchek, S M; Eisen, A; Elsafy, F; Fein, L E; Fielding, A; Ford, J M; Friedman, S; Gelmon, K A; Gianni, L; Gnant, M; Hollingsworth, S J; Im, S-A; Jager, A; Jóhannsson, Ó Þ; Lakhani, S R; Janni, W; Linderholm, B; Liu, T-W; Loman, N; Korde, L; Loibl, S; Lucas, P C; Marmé, F; Martinez de Dueñas, E; McConnell, R; Phillips, K-A; Piccart, M; Rossi, G; Schmutzler, R; Senkus, E; Shao, Z; Sharma, P; Singer, C F; Španić, T; Stickeler, E; Toi, M; Traina, T A; Viale, G; Zoppoli, G; Park, Y H; Yerushalmi, R; Yang, H; Pang, D; Jung, K H; Mailliez, A; Fan, Z; Tennevet, I; Zhang, J; Nagy, T; Sonke, G S; Sun, Q; Parton, M; Colleoni, M A; Schmidt, M; Brufsky, A M; Razaq, W; Kaufman, B; Cameron, D; Campbell, C; Tutt, A N J
